To discover mAbs sensitive to these tumor-specific sites, Alberti et al. employed a deletion mutagenesis strategy to remove the immunodominant regions of Trop2 and then selected mAbs by multiple methods 36. The gene discussed is TACSTD2; the disease is neoplasm.